This HTML5 document contains 85 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/drugbank/
n23http://linked.opendata.cz/resource/mesh/concept/
n25http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/national-drug-code-directory/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n26http://www.drugs.com/
n21http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/chebi/
n7http://www.rxlist.com/cgi/generic/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/pubchem-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01577/identifier/pubchem-substance/

Statements

Subject Item
n2:DB01577
rdf:type
n3:Drug
n3:description
Methamphetamine is a psychostimulant and sympathomimetic drug. It is a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.
n3:dosage
n11:271B575D-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA: Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 2003 Jan;49(1):121-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12507968 # McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM: The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005 Sep;100(9):1320-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16128721 # Bennett BA, Hollingsworth CK, Martin RS, Harp JJ: Methamphetamine-induced alterations in dopamine transporter function. Brain Res. 1998 Jan 26;782(1-2):219-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9519266 # Hasan AA, Ciancio S: Relationship between amphetamine ingestion and gingival enlargement. Pediatr Dent. 2004 Sep-Oct;26(5):396-400. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15460293 # Shaner JW: Caries associated with methamphetamine abuse. J Mich Dent Assoc. 2002 Sep;84(9):42-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12271905
n3:group
approved illicit
n3:halfLife
The biological half-life has been reported in the range of 4 to 5 hours.
n3:indication
For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.
owl:sameAs
n21:DB01577 n24:DB01577
dcterms:title
Methamphetamine
adms:identifier
n9:Methamphetamine n12:10836 n13:46508541 n14:0378-8115-01 n15:PA450403 n16:DB01577 n17:C07164 n18:6809 n19:10379
n3:mechanismOfAction
Methamphetamine enters the brain and triggers a cascading release of norepinephrine, dopamine and serotonin. To a lesser extent methamphetamine acts as a dopaminergic and adrenergic reuptake inhibitor and in high concentrations as a monamine oxidase inhibitor (MAOI). The mechanism of action involved in producing the beneficial behavioral changes seen in hyperkinetic children receiving methamphetamine is unknown.
n3:packager
n25:271B5759-363D-11E5-9242-09173F13E4C5 n25:271B575A-363D-11E5-9242-09173F13E4C5 n25:271B5757-363D-11E5-9242-09173F13E4C5 n25:271B5758-363D-11E5-9242-09173F13E4C5 n25:271B5756-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Excretion occurs primarily in the urine, the rate of which is dependent on urine pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine.
n3:synonym
(AlphaS)-N,alpha-dimethylbenzeneethanamine d-phenylisopropylmethylamine Methamphetamine Metanfetamina Métamfétamine d-N-methylamphetamine (αS)-N,α-dimethylbenzeneethanamine d-1-phenyl-2-methylaminopropane Methamphetaminum Dextromethamphetamine Metamfetaminum d-deoxyephedrine (+)-(S)-N-α-dimethylphenethylamine (S)-N,α-dimethylbenzeneethanamine (+)-(S)-N-alpha-Dimethylphenethylamine methyl-β-phenylisopropylamine (S)-N,alpha-Dimethylbenzeneethanamine d-desoxyephedrine Methyl-beta-phenylisopropylamine
n3:toxicity
Manifestations of acute overdosage with methamphetamine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia, and rhabdomyolysis. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma.
n3:salt
n3:synthesisReference
Nobuyuki Shigetoh, Hiroshi Nakayama, Jinsei Miyazaki, Tadayasu Mitsumata, "Labelling colors for detecting cocaine or methamphetamine, method of preparing the same and detector for cocaine or methamphetamine." U.S. Patent US5571727, issued October, 1981.
n22:hasConcept
n23:M0013551
foaf:page
n7:methamphetamine.htm n26:methamphetamine.html
n3:IUPAC-Name
n4:271B5762-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5768-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5767-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5764-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5765-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5766-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5760-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B575E-363D-11E5-9242-09173F13E4C5 n4:271B5761-363D-11E5-9242-09173F13E4C5 n4:271B5777-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B575F-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B5778-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B576E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B576F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5769-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B576A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B576C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B576B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B576D-363D-11E5-9242-09173F13E4C5
n3:absorption
Methamphetamine is rapidly absorbed from the gastrointestinal tract with peak methamphetamine concentrations occurring in 3.13 to 6.3 hours post ingestion. Methamphetamine is also well absorbed following inhalation and following intranasal administration. It is distributed to most parts of the body. Because methamphetamine has a high lipophilicity it is distributed across the blood brain barrier and crosses the placenta.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
537-46-2
n3:category
n3:containedIn
n10:271B575B-363D-11E5-9242-09173F13E4C5 n10:271B575C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5773-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5775-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5776-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5772-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5771-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5774-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5763-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5770-363D-11E5-9242-09173F13E4C5